Keio University · Medicine
Professor Eiji Kikuchi's research lab specializes in urological oncology, with a primary focus on identifying and validating prognostic biomarkers in urothelial carcinoma and prostate cancer. The lab investigates the clinical significance of pathological factors such as lymphovascular invasion (LVI), tumor volume, and CD44v9 expression in predicting disease progression and survival outcomes. A key direction involves exploring the role of cancer stem cell markers and molecular pathways—particularly the CD44v9-xCT system—in modulating chemotherapy response and metastasis in muscle-invasive bladder cancer. The lab also evaluates the impact of surgical and reconstructive urological procedures on patient-reported outcomes and quality of life.
Figures are computed from collected data and may differ slightly.
LVI was an independent predictor of clinical outcomes in nonmetastatic patients who underwent RNU for UTUC. Assessment of LVI may help identify patients who could benefit from multimodal therapy after RNU. After confirmation, LVI should be included in staging of UTUC.
TV provides no independent prognostic information when considered in multivariate analysis with Gleason score and pathological stage. Measurement of TV before treatment is less likely to characterize prostate cancer accurately than assessment of tumor grade and extent. There seems to be little reason to measure TV routinely in RP specimens.
You have accessJournal of UrologyDiscussed Poster, Monday, May 10, 2004, 8:00am - 12:00 pm1 Apr 2004794: Is Tumor Volume an Independent Prognostic Factor in Clinically Localized Prostate Cancer? Eiji Kikuchi, Makoto Ohori, Thomas M. Wheeler, Kevin M. Slawin, and Peter T. Scardino Eiji KikuchiEiji Kikuchi More articles by this author , Makoto OhoriMakoto Ohori More articles by this author , Thomas M. WheelerThomas M. Wheeler More articles by this author , Kevin M. SlawinKevin M. Slawin More artic
In addition to pathological stage and tumor grade, LVI is an independent prognostic factor for disease specific survival in upper tract TCC. Patients in the high and/or intermediate risk groups may benefit from integrated therapies with surgery and postoperative systemic chemotherapy.
The type of urinary diversion does not appear to be associated with a different QOL by general cancer-related assessment. Urinary function and body image are affected and related to the method used to reconstruct the urinary system.
The prognostic role of CD44v9, a variant isoform of CD44 and a new cell surface marker of cancer stem cells, remains unclear in bladder cancer (BC) patients. Furthermore, limited information is available on the functional role of sulfasalazine (SSZ), which could modulate the CD44v9-xCT system in order to enhance cisplatin (CDDP)-induced cytotoxicity and inhibit the metastatic potential of BC. CD44v9 protein expression was examined immunohistochemically in 63 muscle invasive BC (MIBC) patients wh
There have been several studies on the antitumor activities of vitamin E succinate (alpha-TOS) as complementary and alternative medicine. In the present study, we investigated the cytotoxic effect of alpha-TOS and the enhancement of chemosensitivity to paclitaxel by alpha-TOS in bladder cancer. KU-19-19 and 5637 bladder cancer cell lines were cultured in alpha-TOS and/or paclitaxel in vitro. Cell viability, flow cytometric analysis, and nuclear factor-kappa B (NF-kappaB) activity were analyzed.
Open papers in the app to read, cite, and organize with AI.
